AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37517452 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite biomarkers identified through metabolomics profiling and liquid chromatography-mass spectrometry tests.
Number of subjects: 1024
Study 37517552 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor human milk (DHM)
Number of subjects: 15
Study 37517552 — intervention group
Group type: COMPARATOR
Intervention: Early preterm human milk
Number of subjects: 15
Study 37517552 — intervention group
Group type: COMPARATOR
Intervention: Mature preterm human milk
Number of subjects: 15
Study 37517579 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement with best medical therapy (BMT)
Number of subjects: 63
Study 37517579 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy (BMT)
Number of subjects: 63
Study 37517614 — intervention group
Group type: COMPARATOR
Intervention: Preterm infants
Number of subjects: 102
Study 37517614 — intervention group
Group type: COMPARATOR
Intervention: Covarying network of gut microbiota
Number of subjects: 102
Study 37517614 — intervention group
Group type: COMPARATOR
Intervention: Clostridium_sensu_stricto_1
Number of subjects: 102
Study 37517799 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment of choroidal hypertransmission
Number of subjects: 0
Study 37517799 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment of ELM disruption
Number of subjects: 0
Study 37517799 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment of OPL/INL subsidence
Number of subjects: 0
Study 37517799 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment of hyporeflective wedge-shaped band
Number of subjects: 0
Study 37517799 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative measurement of choroidal hypertransmission
Number of subjects: 0
Study 37517799 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative measurement of RPE attenuation/disruption
Number of subjects: 0
Study 37517799 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal changes for choroidal hypertransmission
Number of subjects: 0
Study 37517799 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal changes for ELM disruption
Number of subjects: 0
Study 37517799 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal changes for EZ disruption
Number of subjects: 0
Study 37517799 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal changes for RPE attenuation/disruption
Number of subjects: 0
Study 37517799 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ability to evaluate changes over time for specific features of iRORA and cRORA
Number of subjects: 0
Study 37517825 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic assay methodology and reporting from 95 reports describing 113 assay results.
Number of subjects: 56
Study 37517875 — intervention group
Group type: EXPERIMENTAL
Intervention: RRMM treatments
Number of subjects: 276
Study 37517875 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital visits
Number of subjects: 276
Study 37517875 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver presence
Number of subjects: 276
Study 37517875 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportation costs
Number of subjects: 276
Study 37518058 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental enteral protein (1.2 g/kg/day) starting from ICU day 5 until ICU discharge or ICU day 90
Number of subjects: 2502
Study 37518058 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition formula (0.8-1.2 g/kg/day) without supplemental protein
Number of subjects: 2502
Study 37518058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups receive primary enteral formula with a maximum protein of 1.2 g/kg/day
Number of subjects: 2502
Study 37518060 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg QD on days 1-4; Gefitinib 250 mg QD on days 5-15, combined with Apatinib 500 mg QD on days 12-15.
Number of subjects: 22
Study 37518076 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose docosahexaenoic acid (DHA) enteral supplementation during the neonatal period
Number of subjects: 0
Study 37518076 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 37518076 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DHA enteral supplementation
Number of subjects: 0
Study 37518082 — intervention group
Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation (OKS) - 2 weekly sessions for 10 weeks using virtual reality glasses to project OKS at a preset speed.
Number of subjects: 102
Study 37518082 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment - virtual reality video without OKS.
Number of subjects: 102
Study 37518089 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin administered as colistin methanesulfonate (CMS) intravenously at standard dosing.
Number of subjects: 30
Study 37518089 — intervention group
Group type: COMPARATOR
Intervention: No ECMO (control group).
Number of subjects: 30
Study 37518975 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal elastase-1 (FE-1) levels >500 µg/g
Number of subjects: 42
Study 37518975 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain posttransplant
Number of subjects: 42
Study 37518975 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis between weight gain and FE-1, pretransplant C-peptide levels, or duration of diabetes
Number of subjects: 42
Study 37519033 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic glucose (HG) 75%
Number of subjects: 116
Study 37519033 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tetradecyl sulfate (STS) 0.05%
Number of subjects: 116
Study 37519033 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tetradecyl sulfate (STS) 0.1%
Number of subjects: 116
Study 37519033 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tetradecyl sulfate (STS) 0.15%
Number of subjects: 116
Study 37519897 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive digital tools (digital diaries and/or wearables)
Number of subjects: 157
Study 37519897 — intervention group
Group type: COMPARATOR
Intervention: No supportive digital tools
Number of subjects: 157
Study 37519971 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative endodontic therapy (RET) with modified triple antibiotic paste (mTAP)
Number of subjects: 39
Study 37519971 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative endodontic therapy (RET) with Metapex™
Number of subjects: 39
Study 37519971 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide eugenol (ZOE) pulpectomy
Number of subjects: 39
Study 37520177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh mango
Number of subjects: 34
Study 37520177 — intervention group
Group type: COMPARATOR
Intervention: Dried mango
Number of subjects: 34
Study 37520237 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy (MDMA-AT)
Number of subjects: 20
Study 37520237 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (control)
Number of subjects: 20
Study 37520311 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised field-based 8 min exercise challenge test (ECT) at 85% maximal heart rate
Number of subjects: 60
Study 37520311 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstandardised field-based exercise challenge test (ECT)
Number of subjects: 60
Study 37520311 — intervention group
Group type: COMPARATOR
Intervention: Eucapnic voluntary hyperpnoea (EVH) and methacholine bronchial provocation test (BPT)
Number of subjects: 60
Study 37520311 — intervention group
Group type: COMPARATOR
Intervention: Standardised field-based ECT
Number of subjects: 60
Study 37520311 — intervention group
Group type: COMPARATOR
Intervention: Unstandardised field-based ECT
Number of subjects: 60
Study 37520311 — intervention group
Group type: COMPARATOR
Intervention: EVH and methacholine BPT
Number of subjects: 60
Study 37520411 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg IV sotrovimab
Number of subjects: 81
Study 37520420 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG/3TC
Number of subjects: 741
Study 37520420 — intervention group
Group type: COMPARATOR
Intervention: TAF-based regimen
Number of subjects: 741
Study 37520827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amount/moderate-intensity exercise (10 kcal/kg/week at 50% peak)
Number of subjects: 0
Study 37520827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amount/moderate-intensity exercise
Number of subjects: 0
Study 37520827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amount/vigorous-intensity exercise
Number of subjects: 0
Study 37520827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amount/vigorous-intensity exercise
Number of subjects: 0
Study 37520827 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and lifestyle intervention
Number of subjects: 0
Study 37521160 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit and Stay Quit Monday intervention
Number of subjects: 50
Study 37521160 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard smoking cessation services)
Number of subjects: 50
Study 37521410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich coral calcium (HRCC) capsules (low, medium, and high doses)
Number of subjects: 16
Study 37521410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich coral calcium (HRCC) capsules
Number of subjects: 16
Study 37521498 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting recreational digital screen use to less than 3 hours/week/person
Number of subjects: 164
Study 37521498 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 164
Study 37522086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vienna TAVI system
Number of subjects: 10
Study 37522226 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 0
Study 37522226 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 0
Study 37522226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg
Number of subjects: 0
Study 37522226 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Number of subjects: 0
Study 37522226 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments combined
Number of subjects: 0
Study 37522330 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoLight Skylife phototherapy device
Number of subjects: 0
Study 37522330 — intervention group
Group type: COMPARATOR
Intervention: Existing phototherapy treatment
Number of subjects: 0
Study 37522361 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Block
Number of subjects: 40
Study 37522361 — intervention group
Group type: COMPARATOR
Intervention: Control (fixed appliance)
Number of subjects: 40
Study 37522415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 240 IU inhaled
Number of subjects: 0
Study 37522415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 5 IU intravenous
Number of subjects: 0
Study 37522415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 10 IU intramuscular
Number of subjects: 0
Study 37522415 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood collected into EDTA tubes
Number of subjects: 0
Study 37522415 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood collected into lithium heparin (LH) tubes
Number of subjects: 0
Study 37522415 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood collected into EDTA-containing collection tubes
Number of subjects: 0
Study 37522415 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood from late-stage pregnancy compared to nonpregnant participants
Number of subjects: 0
Study 37522479 — intervention group
Group type: EXPERIMENTAL
Intervention: rIX-FP (IDELVION) at 50 IU/kg once a week
Number of subjects: 1
Study 37522479 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified rIX-FP regimen at 40 IU/kg twice/week
Number of subjects: 1
Study 37522931 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomo-AC
Number of subjects: 23
Study 37522931 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomo-NoAC
Number of subjects: 23
Study 37522931 — intervention group
Group type: EXPERIMENTAL
Intervention: Planar
Number of subjects: 23
Study 37522931 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT/CT
Number of subjects: 23
Study 37523143 — intervention group
Group type: EXPERIMENTAL
Intervention: Vutrisiran
Number of subjects: 0
Study 37523143 — intervention group
Group type: COMPARATOR
Intervention: Control (external placebo group from the APOLLO study)
Number of subjects: 0
Study 37523163 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemie Prep for Parents (P3) program
Number of subjects: 120
Study 37523163 — intervention group
Group type: COMPARATOR
Intervention: Control group (patient education webpages from the American College of Obstetricians and Gynecologists)
Number of subjects: 120
Study 37523175 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-Only iLet Bionic Pancreas
Number of subjects: 0
Study 37523194 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hemodialysis (HD)
Number of subjects: 0
Study 37523194 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 0
Study 37523194 — intervention group
Group type: COMPARATOR
Intervention: In-center HD
Number of subjects: 0
Study 37523315 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist educational program
Number of subjects: 0
Study 37523315 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer educational program
Number of subjects: 0
Study 37523315 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 37523426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery within 4 weeks
Number of subjects: 292
Study 37523426 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery 1 year later)
Number of subjects: 292
Study 37523429 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated low-level red-light (RLRL) therapy
Number of subjects: 143
Study 37523429 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study 37523477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pills (OCPs)
Number of subjects: 3723
Study 37523477 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous use of OCPs
Number of subjects: 3723
Study 37523477 — intervention group
Group type: COMPARATOR
Intervention: OCPs
Number of subjects: 3723
Study 37523477 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of OCPs
Number of subjects: 3723
Study 37523623 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal deep learning (DL) classifier using wide OCT optic nerve head cube scans
Number of subjects: 633
Study 37523623 — intervention group
Group type: COMPARATOR
Intervention: Texture-based en face image
Number of subjects: 633
Study 37523623 — intervention group
Group type: COMPARATOR
Intervention: RNFL thickness map
Number of subjects: 633
Study 37523623 — intervention group
Group type: COMPARATOR
Intervention: cSLO image
Number of subjects: 633
Study 37523623 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal DL model in highly myopic eyes
Number of subjects: 633
Study 37523623 — intervention group
Group type: COMPARATOR
Intervention: Texture en face image in highly myopic eyes
Number of subjects: 633
Study 37523623 — intervention group
Group type: COMPARATOR
Intervention: RNFL in highly myopic eyes
Number of subjects: 633
Study 37523623 — intervention group
Group type: COMPARATOR
Intervention: cSLO image models in highly myopic eyes
Number of subjects: 633
Study 37523624 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Chemoradiation with Pazopanib
Number of subjects: 0
Study 37523624 — intervention group
Group type: COMPARATOR
Intervention: Preoperative Chemoradiation without Pazopanib
Number of subjects: 0
Study 37523661 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (20 mg orally once daily) plus Pembrolizumab (200 mg intravenously every 3 weeks)
Number of subjects: 0
Study 37523661 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (doxorubicin or paclitaxel)
Number of subjects: 0
Study 37523661 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab
Number of subjects: 0
Study 37523939 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary pharmacological optimization in the context of a Comprehensive Geriatric Assessment (CGA) with usual care follow-up (∼3 and ∼6 months)
Number of subjects: 104
Study 37524096 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg oral daily for 54 weeks
Number of subjects: 1545
Study 37524096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1545
Study 37524096 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus in very-high-risk group
Number of subjects: 1545
Study 37524096 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus in intermediate-high-risk group
Number of subjects: 1545
Study 37524096 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 1545
Study 37524101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose plus tranexamic acid
Number of subjects: 413
Study 37524101 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus placebo
Number of subjects: 413
Study 37524101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid plus placebo
Number of subjects: 413
Study 37524101 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 413
Study 37524110 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 76
Study 37524110 — intervention group
Group type: COMPARATOR
Intervention: Exenatide
Number of subjects: 76
Study 37524198 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac disease (CeD) patients
Number of subjects: 30
Study 37524198 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 30
Study 37524201 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7442 (tixagevimab/cilgavimab) 300 or 600 mg intramuscularly or 300 or 1000 mg intravenously
Number of subjects: 40
Study 37524201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 37524201 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7442 (tixagevimab/cilgavimab)
Number of subjects: 40
Study 37524230 — intervention group
Group type: EXPERIMENTAL
Intervention: RG6346 at 1.5 mg/kg
Number of subjects: 43
Study 37524230 — intervention group
Group type: EXPERIMENTAL
Intervention: RG6346 at 3.0 mg/kg
Number of subjects: 43
Study 37524230 — intervention group
Group type: EXPERIMENTAL
Intervention: RG6346 at 6.0 mg/kg
Number of subjects: 43
Study 37524230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 37524522 — intervention group
Group type: EXPERIMENTAL
Intervention: PAH group
Number of subjects: 100
Study 37524522 — intervention group
Group type: COMPARATOR
Intervention: Normal PAP group
Number of subjects: 100
Study 37524523 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMEOX device with telecare training
Number of subjects: 22
Study 37524953 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab plus CAPOX
Number of subjects: 507
Study 37524953 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus CAPOX
Number of subjects: 507
Study 37524953 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab
Number of subjects: 507
Study 37524953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study 37525000 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Number of subjects: 674
Study 37525000 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 674
Study 37525110 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal mindfulness program (8-week course)
Number of subjects: 102
Study 37525110 — intervention group
Group type: COMPARATOR
Intervention: Usual standard prenatal care (Control)
Number of subjects: 102
Study 37525125 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual group-based acceptance and commitment therapy (n=35)
Number of subjects: 70
Study 37525161 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Confident Athletes (BCA) intervention
Number of subjects: 1036
Study 37525161 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 1036
Study 37525207 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted manual-assisted problem-solving intervention (CMAP) plus enhanced treatment as usual (E-TAU)
Number of subjects: 901
Study 37525207 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (E-TAU)
Number of subjects: 901
Study 37525253 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile and technology-assisted aftercare intervention
Number of subjects: 24
Study 37525253 — intervention group
Group type: COMPARATOR
Intervention: Standard services available for individuals discharging from a CSU
Number of subjects: 24
Study 37525257 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 100
Study 37525257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 37525258 — intervention group
Group type: EXPERIMENTAL
Intervention: SV prevention intervention at intervention campuses
Number of subjects: 28
Study 37525267 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation intervention by certified practice facilitators (PFs) over 12 months
Number of subjects: 32
Study 37525267 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation intervention by certified practice facilitators (PFs)
Number of subjects: 32
Study 37525278 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous leukocyte- and platelet-rich fibrin (L-PRF) membranes
Number of subjects: 0
Study 37525278 — intervention group
Group type: COMPARATOR
Intervention: Commercially available fibrin sealants
Number of subjects: 0
Study 37525298 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated participants (n=471, 62%) who self-reported accessing BN/BED treatment at some point in their lives
Number of subjects: 762
Study 37525298 — intervention group
Group type: COMPARATOR
Intervention: Untreated participants (n=291, 38%) who never accessed treatment
Number of subjects: 762
Study 37525298 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with a history of inpatient or residential treatment
Number of subjects: 762